Multiple Biomarkers in Undiagnosed Pleural Effusion

This study has been terminated.
(The study was terminated on completion of the Pilot Study phase.)
Sponsor:
Information provided by (Responsible Party):
Fujirebio Diagnostics, Inc.
ClinicalTrials.gov Identifier:
NCT00316134
First received: April 18, 2006
Last updated: November 7, 2011
Last verified: November 2011
  Purpose

The purpose of this clinical trial is to evaluate the ability of various biomarkers measured in serum and/or pleural fluids to estimate the risk of finding cancer in patients with undiagnosed pleural effusions. An algorithm for prediction of the risk of finding cancer in the patient using an optimal combination of markers will be developed, and patients will be categorized as having a low, moderate, or high risk of finding cancer that might be used to more effectively triage patients.


Condition Intervention
Pleural Effusion
Pleural Effusion, Malignant
Procedure: Procedure/Surgery

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Multiple Biomarkers in Serum and Pleural Fluid to Estimate the Probability of Cancer in Patients Presenting With an Undiagnosed Pleural Effusion

Resource links provided by NLM:


Further study details as provided by Fujirebio Diagnostics, Inc.:

Biospecimen Retention:   Samples Without DNA

Serum and pleural fluids


Enrollment: 200
Study Start Date: March 2006
Study Completion Date: February 2008
Groups/Cohorts Assigned Interventions
Pts scheduled to remove pleural fluid Procedure: Procedure/Surgery
Diagnostic and/or therapeutic procedure to remove pleural fluid.

Detailed Description:

Approximately 1.6 million cases of pleural effusion are seen in the US per year, with ~210,000 of those cases due to underlying malignancy. Pleural fluids have traditionally been divided into two types: transudative and exudative. The most common causes of transudative pleural effusion are congestive heart failure and cirrhosis. Common causes of exudative pleural effusion include malignancy, pneumonia, pulmonary embolism and viral infection. One study found that 42% of all exudative effusions were due to malignancy, and another found that malignancy was the underlying cause of 24% of all effusions. Differential diagnosis of the various causes of effusions is complex and includes gross appearance of the pleural fluid (PF), differential cell count, cytology, glucose and LDH levels, and sometimes adenosine deaminase (ADA) levels. In addition, spiral CT scans, bronchoscopy, thoracoscopy, needle biopsy of the pleura, and video assisted thoracoscopy (VATS) are all utilized to determine the underlying cause of pleural fluid accumulation. These procedures are expensive and may be traumatic to patients. In approximately 20% of patients presenting with pleural fluid accumulation, no underlying cause will be established. Despite promising results published in peer-reviewed journals over the last two decades, serum biomarkers have not gained acceptance as a standard of care in the management of patients with lung cancer, mesothelioma, or pleural effusion. The purpose of this clinical trial is to evaluate the ability of various biomarkers measured in serum and/or pleural fluids to estimate the risk of finding cancer in patients with undiagnosed pleural effusions. An algorithm for prediction of the risk of finding cancer in the patient using an optimal combination of markers will be developed, and patients will be categorized as having a low, moderate, or high risk of finding cancer that might be used to more effectively triage patients. For example, a high risk of cancer may be used to justify more invasive or expensive procedures, such as spiral CT scans and thoracoscopy.

This is a prospective, multi-center, double-blind, statistically powered clinical trial that will enroll patients scheduled to undergo a procedure for removal of fluid from a pleural effusion (i.e. thoracentesis, thoracoscopy, image guided thoracentesis, thoracotomy, chest tube placement, Pleurex® catheter insertion, etc.).

The primary objective of the study is to evaluate the ability of multiple biomarkers in serum and/or pleural fluid to estimate the risk of finding cancer in subjects presenting with an undiagnosed pleural effusion (i.e. unknown origin).

The secondary objective of the study is to compare the ability of multiple biomarkers in serum and/or pleural fluid combined with pleural fluid cytology and other laboratory results to the use of the multiple biomarkers alone to estimate the risk of finding cancer in subjects presenting with an undiagnosed pleural effusion.

The research objectives of the study are the evaluation of the utility of multiple biomarkers in serum and/or pleural fluid to predict the tissue of origin in subjects with cancer who presented with an undiagnosed pleural effusion and comparison of these results to pleural fluid cytology. Correlation of the biomarker levels in the serum and pleural fluid will be evaluated as well.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

N/A - study was closed

Criteria

Inclusion Criteria:

TRAINING SET INCLUSION CRITERIA

  • Subjects able to understand and sign Informed Consent;
  • Males or females >18 years of age;
  • Have a pleural effusion of known or unknown origin;
  • Scheduled for a diagnostic and/or therapeutic procedure to remove pleural fluid.

VALIDATION SET INCLUSION CRITERIA

  • Subjects able to understand and sign Informed Consent;
  • Males or females >18 years of age;
  • Have a pleural effusion of unknown origin;
  • Scheduled for a diagnostic procedure to remove pleural fluid.

Exclusion Criteria:

TRAINING SET EXCLUSION CRITERIA

  • For Subjects currently receiving chemotherapy and/or radiation therapy- Subjects who have received chemotherapy and/or radiation therapy must have completed these modalities one month before entering the study.
  • Females known to be pregnant;
  • Already entered into the study;
  • Unable or unwilling to provide informed consent or is there a high risk that the subject may not comply with the protocol requirements

VALIDATION SET EXCLUSION CRITERIA

  • For Subjects currently receiving chemotherapy and/or radiation therapy- Subjects who have received chemotherapy and/or radiation therapy must have completed these modalities one month before entering the study.
  • Females known to be pregnant;
  • Already entered into the study;
  • Unable or unwilling to provide informed consent or is there a high risk that the subject may not comply with the protocol requirements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00316134

Locations
United States, Pennsylvania
Fujirebio Diagnostics, Inc
Malvern, Pennsylvania, United States, 19355
Sponsors and Collaborators
Fujirebio Diagnostics, Inc.
Investigators
Study Director: Jeffrey Allard, PhD Fujirebio Diagnostics, Inc.
  More Information

No publications provided

Responsible Party: Fujirebio Diagnostics, Inc.
ClinicalTrials.gov Identifier: NCT00316134     History of Changes
Other Study ID Numbers: FDI-02 Pleural Effusion Study
Study First Received: April 18, 2006
Last Updated: November 7, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Fujirebio Diagnostics, Inc.:
Pleural Diseases
Pleural Effusion
Pleural Effusion, Malignant
Pleural Neoplasms
Neoplasms, Pleural

Additional relevant MeSH terms:
Pleural Effusion
Pleural Effusion, Malignant
Pleural Diseases
Respiratory Tract Diseases
Pleural Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms

ClinicalTrials.gov processed this record on July 22, 2014